Tirzepatide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | ||
==Side Effects== | |||
*Pancreatitis | |||
*Nausea | |||
*Vomiting | |||
*Abdominal pain | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 05:25, 20 August 2022
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment
Side Effects
- Pancreatitis
- Nausea
- Vomiting
- Abdominal pain